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Aim: Diabetic peripheral neuropathy (DPN) is a common, severe microvascular
complication of diabetes. Our study was to assess prevalence and risk factors for DPN
in subjects with type 2 diabetes from 14 different countries.
Methods: A total of 2,733 subjects with type 2 diabetes aged 18–65 years (45.3%
men, mean duration of diabetes = 8.8 years) were included to perform this International
Prevalence and Treatment of Diabetes and Depression (INTERPRET-DD) study in 14
countries. After a structured questionnaire was used in face-to-face interviews to collect
sociodemographic characteristics and medical records of the participating subjects,
laboratory tests were carried out for clinical measurement. Depressive symptoms were
diagnosed and measured using the Patient Health Questionnaire-9. The potential
risk factors for DPN were determined by multilevel mixed-effects logistic regression,
accounting for clustering of participants within the country. Robustness of the estimates
was assessed by sensitivity analysis.
Results: The overall prevalence of DPN across different countries was 26.71%,
whereas country-specific prevalences showed considerable variation. Multivariate
analysis revealed that duration of diabetes (OR: 1.08 per 1-year increase, 95% CI:
1.06–1.09), poor glycemic control (OR: 1.11 per 1% increase in HbA1c, 95% CI:
1.05–1.18), and history of hypertension (OR: 1.58, 95% CI: 1.18–2.12), cardiovascular
disease (OR: 2.07, 95% CI: 1.55–2.78) and depressive symptoms (OR: 1.92, 95%
CI: 1.43–2.58) were independently and positively associated with the risk of DPN.
Sensitivity analyses including or excluding patients from countries with extreme low or
high prevalence of DPN yielded similar estimates in terms of trend and magnitude.
Conclusions: This international study illustrates that more than a quarter of individuals
with type 2 diabetes developed DPN. The prevalence was positively associated with the
duration of diabetes, poor glycemic control, and history of hypertension, cardiovascular
disease and depressive symptoms.
Keywords: diabetic peripheral neuropathy, prevalence, risk factors, depressive symptoms, diabetes mellitus
Lu et al. Prevalence for Diabetic Peripheral Neuropathy
INTRODUCTION
Diabetes mellitus is a major public health issue. An estimated
451 million people were diagnosed with diabetes worldwide in
2017, and the number will increase to 693 million by 2045 (1).
Compared with other chronic diseases, diabetes causes greater
mortality, morbidity, disability and financial loss due to its
complications (2). Diabetic peripheral neuropathy (DPN) is one
of the most common and severe microvascular complications of
diabetes (3). As a major contributor to peripheral nerve injury
(4), DPN impairs quality of life and potentiates risks of disability
in diabetic subjects (5). However, the prevalence and the risk
factors of DPN on a global scale, especially in low- and middle-
income countries, remain unclear.
Previous studies showed a fairly wide range: 8–75%, for
the prevalence of DPN in diabetic patients (6–11). Likely, the
heterogeneity in anthropometry, culture and ethnicity might
have been confounded to these considerable disparities. Many
epidemiological studies have examined clinical correlates of DPN
(6, 7, 10, 12, 13). Apart from vascular risk factors (14), depressive
symptoms have also been implicated in the pathogenesis of
DPN (15). However, the prevalence and risk factors for diabetes-
associated DPN have not been systematically investigated in
adults of multiple countries.
The International Prevalence and Treatment of Diabetes
and Depression Study (INTERPRET-DD) was conducted in 14
countries under the auspices of the Dialogue on Diabetes and
depression (http://diabetesanddepression.org/). The study was
aimed to investigate the prevalence and treatment of depression
in type 2 diabetic patients (16). Thus, this study has provided us
with an unprecedented opportunity to investigate the prevalence
and risk factors of DPN as a common and severe complication
of type 2 diabetes in multiple countries with different socio-
economic development and cultural settings.
METHODS
Study Population
The INTERPRET-DD study is an international study conducted
between 2013 and 2015 in 14 countries including Argentina,
Bangladesh, China, Germany, India, Italy, Kenya, Mexico,
Pakistan, Poland, Russia, Serbia, Uganda, Ukraine. A detailed
description of the research design and data collection procedure
of the INTERPRET-DD study has been published previously
(17). Briefly, a sample of consecutive outpatient clinic attenders
with type 2 diabetes mellitus (T2DM) at each of the study sites
were invited by the treating physician or diabetologist in the
diabetes clinics to participate in the study between September
2013 and May 2015, with the purpose of enrolling a total of 200
T2DM patients in each country. The collaborating sites recruited
the teams of investigators from leading centers of excellence in
each country, with at least one psychiatrist and endocrinologist
included. Diabetes clinics were based in either secondary or
tertiary care centers, depending on the facilities available in each
country. T2DM patients aged 18–65 years and diagnosed at least
12 months before enrollment were eligible study participants.
The exclusion criteria were: diagnosis of T2DM <12 months;
diagnosis of type 1 diabetes; inability to complete the survey
tools because of communication or cognitive difficulties; any
life-threatening or serious conditions (e.g., cancer, stroke in
the last 6 months); being currently admitted or planning an
admission for inpatient care to a hospital (unless admitted for
diabetes self-management); pregnant women or women who
gave birth within the last 6 months and clinically diagnosis
of dependency on alcohol or other substances (not tobacco)
or a diagnosis of schizophrenia. A total of 2,783 individuals
with T2DM agreed to participate in the study, at a response
rate of 92.3%. Response rates differed among countries, ranging
from 64.7% (Ukraine) to 100% in Uganda, Mexico and India.
However, only 2,733 participants were included in the final
analysis, with 50 participants being excluded due to incomplete
records. Institutional review board approval was obtained for
each center in each country prior to protocol implementation.
Written informed consent was obtained from all participants.
Data Collection
Investigators from each site in each country completed an
information form for each eligible individual. This form included
information from medical records, such as age, duration of
diabetes, family history of diabetes and presence/history of
diabetes complications, which included cardiovascular disease,
peripheral neuropathy, retinopathy, renal disease, peripheral
vascular disease as well as associated disorders. Most recent
measurements of blood pressure, height and weight, and HbA1c
were also recorded. Participants were asked if they lived in
what they considered to be a rural or an urban area, and
reported their highest level of education (higher education was
defined as any college, postgraduate or professional training).
Marital status was defined as married/cohabiting vs. being
single/widowed/divorced. Participants were also asked if they
considered that they had a regular income. DPN was assessed
clinically when participants showed symptoms of sensory
abnormalities, tingling, numbness, burning pain with paresthesia
in both lower extremities or pain of distal extremities lasting for
more than 3 months through neurophysiological study, which
was recorded in the medical records according to standard
criteria (18). Body mass index (BMI) was calculated as weight
in kilograms divided by height in meters squared. Hypertension
was defined as self-reported history of hypertension, taking
antihypertensive drugs, systolic BP ≥ 140 mmHg or diastolic
BP ≥ 90 mmHg. The Patient Health Questionnaire-9 (PHQ-
9), a self-report measure of depression symptoms based on
the American Psychiatric Association’s DSM-IV criteria for
the diagnosis of a depressive episode, was used to identify
probable depression (19). The presence of moderate/severe
depressive symptomatology was defined as PHQ-9 scores >
9 according to a previous study (17). All questionnaires
were completed with standard self-complete methods in
appropriate languages, or assisted one-to-one collection. Where
no existing translation/cultural adaption of the questionnaire
was available, it was adapted using standard forward/back
translation procedures. Moreover, questionnaires were ensured
to be culturally applicable by each country’s investigators through
development of several iterative stages, including discussion and
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FIGURE 1 | Prevalence of diabetic neuropathy by country.
testing by a range of healthcare professionals and T2DM patients
and concentrating on the meaning of terms as well as language.
Statistical Analysis
All analyses were performed using Stata version 15.1 (StataCorp
LP, College Station, TX, USA). A two-sided P-value of< 0.05 was
considered statistically significant.
Prevalence of DPN
We first estimated the overall and country-specific prevalences of
DPN. Participants were categorized into six age groups: 18–39,
40–45, 46–50, 56–60 and 61–65 years old. The gender-, age- and
residence-specific prevalences were also calculated.
Cross-Sectional Analysis
Continuous variables were shown as means (standard deviation,
SD) and categorical variables were presented as frequencies and
percentages. Student t-test and χ2 test were used to compare
continuous and categorical variables between participants with
and without DPN, respectively. Multilevel mixed-effects logistic
regression accounting for clustering of participants within the
same country (meqrlogit procedure in Stata) was used to
determine significant risk factors by putting all the covariates
in the model. The multilevel model had explanatory variables at
two levels: country and individual. Associations were reported as
odds ratios (ORs) and 95% confidence intervals (CI). In addition,
we performed a sensitivity analysis to minimize the presence of
a potential bias by excluding participants from countries with
extreme low or high prevalence of DPN.
RESULTS
A total of 2,733 participant aged 18–65 years were included in
estimating the overall prevalence of DPN. The demographic
profile of the study population stratified by countries is
shown in Supplementary Table 1. A slightly lower proportion
of men than women participated in the study (45.41%),
ranging from 23.63% (Russia) to 63.79% (Germany). The
majority of participants (72.5%) were married or cohabiting,
ranging from 58.13% (Mexico) to 86.08% (China). The
69.0% participants had higher education, ranging from
42.71% (Russia) to 91.81% (Kenya). Only 16.7% participants
had no regular income, ranging from 1.51% (Russia) to
47.78% (Mexico).
As shown in Figure 1, the overall prevalence of DPN
was 26.71% (95% CI: 25.08–28.40). There was a significant
difference in the prevalence of DPN across different countries
(Figure 1). The participants from Kenya and Italy had the
lowest prevalence of DPN (0.58 and 1.98%, respectively),
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FIGURE 2 | Prevalence of diabetic neuropathy by country after excluding participants from Kenya, Italy, Ukraine and Russia.
TABLE 1 | Prevalence and 95% CI of diabetic neuropathy by gender and living
area.
Overall, % Rural, % Urban, %
Both genders 26.71 (25.08–28.40) 14.72 (11.55–18.58) 28.75 (26.95–30.63)
Male 23.37 (21.09–25.81) 16.25 (11.29–22.82) 24.44 (21.97–27.10)
Female 29.49 (27.23–31.86) 13.68 (9.82–18.71) 32.46 (29.92–35.10)
whereas participants from Ukraine and Russia had the highest
(79.55 and 54.77%, respectively). In the analysis excluding
participants from these four countries, the prevalence of DPN
decreased slightly from the primary analysis (26.71–25.18%,
Figure 2).
As shown in Table 1 and Supplementary Figure 1, women
were more likely than men to have DPN (29.49 vs. 23.37%) in
both the overall sample and in each age group. An increasing
trend in prevalence of DPN with increasing age was observed
and participants in the 56–60 years of age group had the highest
prevalence, with 24.48% (95% CI: 19.86–29.78) in men and
30.75% (95% CI: 26.34–35.54) in women. In addition, those
living in urban areas had a significantly higher prevalence of
DPN than rural areas (28.75 vs. 14.72%, p < 0.05). However,
excluding participants from those four countries modified the
rural prevalence of DPN, which decreased dramatically in both
male and female participants whereas urban prevalence of
DPN increased slightly (Supplementary Table 2). Moreover, the
gender-specific prevalence of DPN converged approximately to
25% in 56–60 and 61–65 years of age groups in the sensitivity
analysis (Supplementary Figure 2).
A total of 2,135 (78.12%) participants had complete data for
all variables of interest. Binary analyses results are presented in
Table 2. Gender, residence, marital status, exercise, duration of
diabetes, insulin use, hypertension, antihypertensive drugs use,
cardiovascular disease, depressive symptoms, HbA1c, SBP, DBP,
and BMI differed significantly between participants with and
without DPN. The multilevel modeling results are shown in
Table 3. In the multivariate analysis, duration of diabetes (OR:
1.08 per 1-year increase, 95% CI: 1.06–1.09), HbA1c (OR: 1.11
per 1% increase, 95% CI: 1.05–1.18), hypertension (OR: 1.58,
95% CI: 1.18–2.12), cardiovascular disease (OR: 2.07, 95% CI:
1.55–2.78), and depressive symptoms (OR: 1.92, 95% CI: 1.43–
2.58) were independently and positively associated with DPN.
Moreover, sensitivity analysis produced similar findings about
risk factors of DPN between including and excluding participants
from participants from Kenya (0.58%), Italy (1.98%), Russia
(54.77%) and Ukraine (79.55%). The modified associations of
duration of diabetes (OR: 1.07 per 1-year increase, 95% CI:
1.05–1.09), HbA1c (OR: 1.11 per 1% increase, 95% CI: 1.04–
1.18), hypertension (OR: 1.40, 95% CI: 1.02–1.91), cardiovascular
disease (OR: 2.08, 95% CI: 1.48–2.92) and depressive symptoms
(OR: 1.85, 95% CI: 1.35–2.56) with DPN were similar to the
estimates from the primary analysis in terms of trend and
magnitude (Supplementary Table 3). In addition, risk factors
for DPN in each country (except Italy, Kenya and Uganda due
to scarce DPN patients) were also analyzed and presented in
Supplementary Figures 3A–K. Specifically, there were country-
dependent positive associations between the primary clinical
correlates and the risks of DPN as follows: the duration of
diabetes in six countries including China, Germany, India,
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TABLE 2 | Characteristics of the participants by diabetic neuropathy status.
Diabetic neuropathy
Variable No (n = 2003) Yes (n = 730) P
Gender, n (%) <0.001
Female 1,052 (52.52) 440 (60.27)
Male 951 (47.48) 290 (39.73)
Age, mean (SD), years 53.44 (9.31)
(n = 2,000)
53.99 (8.71)
(n = 729)
0.170
Location of Residence, n (%) <0.001
Rural 336 (16.77) 58 (7.95)
Urban 1,665 (83.13) 672 (92.05)
Missing 2 (0.10) 0 (0.00)
Marital status, n (%) 0.005
Married/cohabiting 1,482 (73.99) 500 (68.49)
Single/widowed/divorced 518 (25.86) 228 (31.23)
Missing 3 (0.15) 2 (0.27)
Higher education, n (%) 0.280
No 1,370 (68.40) 515 (70.55)
Yes 633 (31.60) 215 (29.45)
Family income status, n (%) 0.500
No regular income 340 (16.97) 116 (15.89)
Regular income 1,662 (82.98) 614 (84.11)
Missing 1 (0.05) 0 (0.00)
Smoking status, n (%) 0.520
Never 1,282 (64.00) 458 (62.74)
Ever 438 (21.87) 175 (23.97)
Current 274 (13.68) 96 (13.15)
Missing 9 (0.45) 1 (0.14)
Exercise (at least weekly), n (%) <0.001
No 713 (35.60) 390 (53.42)
Yes 1,274 (63.60) 338 (46.30)
Missing 16 (0.80) 2 (0.27)
Family history of diabetes, years 0.370
No 685 (34.20) 264 (36.16)
Yes 1,312 (65.50) 466 (63.84)
Missing 6 (0.30) 0 (0.00)
Duration of diabetes, mean (SD) 8.05 (6.42)
(n = 1,933)
10.91 (7.16)
(n = 720)
<0.001
Insulin use, n (%) <0.001
No 1,298 (64.80) 280 (38.36)
Yes 699 (34.90) 449 (61.51)
Missing 6 (0.30) 1 (0.14)
HbA1c, mean (SD), % 7.97 (2.37)
(n = 1,655)
8.70 (2.15)
(n = 617)
<0.001
Hypertension, n (%) <0.001
No 632 (31.55) 171 (23.42)
Yes 1,371 (68.45) 559 (76.58)
Antihypertensive drugs use, n (%) <0.001
No 859 (42.89) 223 (30.55)
Yes 1,118 (55.82) 493 (67.53)
Missing 26 (1.30) 14 (1.92)
SBP, mean (SD), mmHg 130.54 (17.87)
(n = 1,944)
133.09 (18.70)
(n = 708)
0.001
(Continued)
TABLE 2 | Continued
Diabetic neuropathy
Variable No (n = 2003) Yes (n = 730) P
DBP, mean (SD), mmHg 79.38 (10.33)
(n = 1,941)
80.82 (10.68)
(n = 708)
0.002
BMI, mean (SD), kg/m2 28.63 (5.96)
(n = 1,973)
29.43 (6.20)
(n = 725)
0.002
Depressive symptoms, n (%) <0.001
No 1,731 (86.42) 526 (72.05)
Yes 259 (12.93) 200 (27.40)
Missing 13 (0.65) 4 (0.55)
Cardiovascular disease, n (%) <0.001
No 1,710 (85.37) 481 (65.89)
Yes 288 (14.38) 246 (33.70)
Missing 5 (0.25) 3 (0.41)
Pakistan, Russia, and Serbia; the HbA1c concentrations in
Germany and Serbia; hypertension in China; cardiovascular
disease in China and Serbia; and depressive symptoms in
Argentina and Mexico. Furthermore, the following factors
decreased the risks of DPN in respective countries: higher level of
education in Argentina, regular exercise in China, and being not
married in Mexico. In contrast, the following factors potentiated
the risk of DPN in respective countries: higher BMI in Poland and
Russia, being older in Ukraine, and having regular family income
in Bangladesh.
DISCUSSION
Our study indicates that the overall prevalence of DPN in this
multi-ethnic cohort of adults with T2DM was 26.71%, and the
independent and significant correlates of risk factors include
duration of diabetes, poor glycemic control, and history of
hypertension, cardiovascular disease and depressive symptoms.
While the overall prevalence for DPN found in our study for
adults with T2DM was similar to that reported previously (20),
our estimates for prevalence of DPN in different countries varied
substantially: ranging from 0.58% in Kenya to 79.55% in Ukraine.
This large disparity could be attributed to different demography
of the study population, cultural settings, and management of
healthcare. We have also found that female diabetic patients
were more likely to develop DPN than male patients (29.49 vs.
23.37%). This gender difference is consistent with a previous
cross-sectional study (12).
Previous epidemiological studies have shown that the
duration of diabetes and level of hyperglycemia are important
risk factors for DPN (12, 13, 21). In addition, traditional
cardiovascular risk factors (e.g., smoking, hypertension,
dyslipidemia, and higher BMI) have also been reported to
be associated with diabetes-related complications, including
neuropathy (21, 22). Our study has not only confirmed
these findings but also revealed depressive symptoms as a
novel risk factor of DPN. Specifically, we have shown herein
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TABLE 3 | Odds ratios for diabetic neuropathy determined by multilevel mixed-effects logistic regression.
Univariate analysis Multivariate analysis
Variable Crude OR (95% CI) P Adjusted OR (95% CI) P
Age, per 5-year increase 1.15 (1.08–1.22) <0.001 1.04 (0.96–1.13) 0.307
Gender (male vs. female) 0.79 (0.65–0.96) 0.017 0.85 (0.65–1.10) 0.214
Location of residence (urban vs. rural) 1.04 (0.74–1.46) 0.819 1.08 (0.70–1.65) 0.739
Marital status (not married vs. married) 1.16 (0.94–1.43) 0.175 0.94 (0.72–1.23) 0.653
Higher education (yes vs. no) 0.66 (0.53–0.82) <0.001 0.77 (0.58–1.01) 0.062
Regular family income (yes vs. no) 0.88 (0.67–1.14) 0.330 1.26 (0.87–1.82) 0.217
Smoking status
Ever vs. never 1.60 (1.25–2.04) <0.001 1.34 (0.98–1.83) 0.069
Current vs. never 0.93 (0.69–1.26) 0.649 1.10 (0.76–1.59) 0.602
Higher exercise level (yes vs. no) 0.70 (0.57–0.86) 0.001 0.93 (0.72–1.20) 0.582
Family history of diabetes (yes vs. no) 1.12 (0.91–1.37) 0.291 0.96 (0.75–1.24) 0.759
Duration of diabetes, per 1-year increase 1.08 (1.07–1.10) <0.001 1.08 (1.06–1.09) <0.001
HbA1c, per 1% increase 1.17 (1.11–1.23) <0.001 1.11 (1.05–1.18) <0.001
Hypertension (yes vs. no) 2.13 (1.69–2.68) <0.001 1.58 (1.18–2.12) 0.002
BMI, per 1 kg/m2 increase 1.02 (1.01–1.04) 0.006 1.02 (1.00–1.04) 0.125
Cardiovascular disease 3.00 (2.35–3.84) <0.001 2.07 (1.55–2.78) <0.001
Depressive symptoms (yes vs. no) 2.45 (1.93–3.11) <0.001 1.92 (1.43–2.58) <0.001
that T2DM patients with depressive symptoms doubled the
risk of DPN, independent of a range of social-demographic
factors, duration of diabetes, HbA1c, hypertension, BMI and
cardiovascular disease.
Depressive symptoms are increasing rapidly worldwide
among people with T2DM (23). Our previous study showed that
the prevalence of moderate to severe levels of depression was
17.0% among those subjects (17). Diabetes can aggravate the
symptoms of depression (24) and in turn depressive symptoms
can also increase the risk of T2DM and complications (25).
The recent Evaluation of Diabetes Treatment study has reported
that people with pronounced depressive symptoms and high
alcohol frequency had the highest risk of DPN (26). Indeed,
a number of other studies have also demonstrated that poor
glycemic control modifies the association between depressive
symptoms and DPN among the T2DM population (27, 28).
As mentioned above, the present study has illustrated that
depressive symptoms were independently associated with an
increased risk of DPN after adjusting the glycemic control status.
A recent prospective cohort study with 2-year follow-up has also
shown that depressive symptoms were both associated with poor
glycemic control and incident macrovascular complications (29).
However, our findings should be interpreted with caution due to
the time lag between HbA1c measurement and identification of
depressive symptoms.
Overall and country-specific analyses for risk factors of
DPN in the present INTERPRET-DD study have presented
us with a technical challenge. This was because the current
collaborative study was carried out in 14 different countries
with a large variation in the numbers of participants and cases
of DPN among these countries. These variations might have
been attributable to between-country characteristics and different
cultural experiences of symptoms. Therefore, a sensitivity
analysis was conducted to test the robustness of the overall
analysis, the results of which supported that duration of diabetes,
higher HbA1c, hypertension, and cardiovascular disease and
depressive symptoms were strong independent risk factors of
DPN. Furthermore, the duration of diabetes was the most
common risk factor in six countries and overall analysis, followed
by higher HbA1c, depressive symptoms, higher BMI, and
cardiovascular disease as risk factors in two countries. Consistent
with cross-sectional studies in China (30), Iran (10), Bangladesh
(31) and 16 European countries (32), prolonged diabetes
duration was significantly associated with higher risks of DPN.
This suggests an urgent need for early screening and standardized
management of DPN at a global scale. The identification of
HbA1c, BMI, cardiovascular disease, and depressive symptoms
as risk factors also points to the potential of blood glucose
control, weight management, and prevention of dyslipidemia in
decreasing DPN in specific countries. Thus, it is important to
promote appropriate country-specific physical and psychological
intervention strategies for T2DM-derived DPN.
Univariate analysis revealed that higher education level was
significantly associated with lower risk of DPN, whereas smokers
had elevated risks of DPN. Nevertheless, the significance of
these two associations disappeared in multivariate analysis.
Contrary to that, in the sensitivity analysis, the association
between ever-smokers and risk of DPN remained in multivariate
analysis. Therefore, there was variation in effects of education
and smoking on the risk of DPN, as illustrated by the wider
intervals of estimates in the multivariate analysis and the
variation of findings in the sensitivity analysis. This variation
in effects of education and smoking was likely due to the
heterogeneous clinical profiles of participants in different
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countries and the facts that other risk factors might have
attenuated their influence.
There are several limitations to our study. As this is a cross-
sectional study, we are unable to identify the predictors but only
the correlates of DPN. The limited numbers of participants in
certain countries could have made the estimates of country-
specific prevalence and risk factors of DPN questionable or not
representative to those countries. Nevertheless, the current study
also has several strengths. The INTERPRET-DD study was a
collaborative study carried out simultaneously in 14 different
countries. All collaborating researchers used the same protocol to
collect baseline information, including the complete assessment
of depressive symptoms using a clinically validated scale.
CONCLUSION
The present study indicates that more than a quarter of T2DM
individuals from 14 countries might develop DPN. The most
significant, independent risk factors for the T2DM-associated
DPN included duration of diabetes, poor glycemic control, and
history of hypertension, cardiovascular disease and depressive
symptoms. Our results have demonstrated a large variation
among countries in the prevalence of the target disease and
highlighted depressive symptoms as an important risk factor
of DPN. Our findings will have significant implications in
developing healthcare and treatment of T2DM complications.
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